8-K: Current report filing
Published on February 27, 2019
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2019
OPKO Health, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
001-33528 |
75-2402409 |
||
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number) |
(IRS Employer Identification No.) |
||
4400 Biscayne Blvd. Miami, Florida |
33137 |
|
(Address of Principal Executive Offices) |
(Zip Code) |
|
Registrant’s telephone number, including area code: (305) 575-4100
Not Applicable |
Former name or former address, if changed since last report |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
o
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
ITEM 2.02. |
Results of Operations and Financial Condition. |
|
On February 27, 2019, the Company, issued a press release announcing operating and financial highlights for the quarter ended December 31, 2018. A copy of the press release is attached hereto as Exhibit 99.1.
The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended (“Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 7.01. |
Regulation FD Disclosure. |
|
On February 26, 2019, the Company issued a press release announcing that it will hold a conference call to provide a business update and discuss its fourth quarter and full year ended December 31, 2018 financial and operating results, as well as provide guidance on expected revenues and operating expenses for the first quarter 2019. A copy of the press release is attached hereto as Exhibit 99.2.
The information included herein and in Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits |
|
Exhibit No. |
Description |
|
99.1 |
Press Release of the Company dated February 27, 2019 |
|
99.2 |
Press Release of the Company dated February 26, 2019 |
|
Exhibit List
Exhibit No. |
Description |
|
99.1 |
||
99.2 |
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OPKO Health, Inc. |
|||
By: |
/s/ Adam Logal |
||
Date: February 27, 2019 |
Name: |
Adam Logal |
|
Title: |
Senior Vice President, Chief Financial Officer |
||